Sarepta shares plunge 30% as future of its gene therapy appears at risk

cnbc.com/2025/07/18/sarepta-stock-falls-on-fda-gene-therapy-elevidys-comment.html

Shares of Sarepta Therapeutics plunged more than 30% on Friday as the future of its approved gene therapy treatment appeared at risk.
The Food and Drug Administration will request that the company voluntarily stop all shipments of the treatment, Elevidys, a person familiar with the…

This story appeared on cnbc.com, 2025-07-18 17:54:14.305000.
The Entire Business World on a Single Page. Free to Use →